Telehealth payments

Is Compounded Semaglutide or Tirzepatide Still Legal to Sell? What FDA Has Said, for Telehealth Merchants

FDA's shortage-based allowance for compounders has ended. Here is what FDA itself has said, with dates, and what a processor will ask you because of it.

By VyaPayPublished 7 min read

Not on the strength of the shortage any more, in FDA's stated position as of November 2026. FDA declared both shortages resolved, its transition periods for compounders ran out in 2025, and compounders can no longer rely on the shortage to make essentially copies of the approved drugs. Compounding isn't banned outright, but the essentially-copies limits apply, and FDA says it knows of no lawful basis for compounding with salt forms such as semaglutide sodium. Whether a specific product is lawful is a question for regulatory counsel.

Essentially a copy is the Food, Drug, and Cosmetic Act's term for a compounded drug that duplicates an approved, commercially available one. Under §503A, a pharmacy may not compound essentially copies regularly or in inordinate amounts. While the GLP-1s were in shortage, compounders could rely on the shortage to make copies; FDA's position is that they can't once the shortage is resolved and its transition periods have ended.

What did FDA decide about the GLP-1 shortages?

That both are resolved, with fixed end dates for compounders. FDA first determined the tirzepatide shortage resolved on October 2, 2024 and reaffirmed that on December 19, 2024. It declared the semaglutide shortage resolved on February 21, 2025. Each decision came with a period of enforcement discretion for compounders, set separately for the two federal pathways:

DrugShortage resolved503A period ended503B period ended
TirzepatideOctober 2, 2024 (reaffirmed December 19, 2024)February 18, 2025March 19, 2025
SemaglutideFebruary 21, 2025April 22, 2025May 22, 2025

Outsourcing facilities challenged the decisions in court, and according to reporting on those cases, the courts denied their requests for preliminary injunctions. FDA's dates held.

Status as of November 2026. Shortage decisions: in force. FDA's consumer page on unapproved GLP-1 drugs: content current as of October 1, 2026. Warning letters to telehealth sellers: rounds dated September 2025, February 20, 2026 and June 8, 2026. FDA's proposal not to place semaglutide, tirzepatide and liraglutide on the 503B bulks list: reported May 1, 2026, and not final as far as we know.

Does that mean compounded GLP-1s are banned?

FDA's statements aren't framed as a ban on compounding. What ended is the shortage as a basis for making copies. Section 503A still lets a state-licensed pharmacy or physician compound on a valid prescription for an identified patient. Section 503B still lets outsourcing facilities registered with FDA compound under current good manufacturing practice (CGMP) and FDA inspection, with or without prescriptions, and report their products to FDA.

Both pathways carry limits, and the one at issue here is the essentially-copies restriction. Our reading is that without a shortage to lean on, a compounder making a GLP-1 has to show how its specific product sits within that restriction, and that is a product-by-product question, not one with a single answer for the whole market. How the two pathways differ, and what each means for your underwriting file, is in 503A vs 503B pharmacies for telehealth.

What FDA says about salt forms and "same as" claims

FDA has drawn two lines on its page "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (content current as of October 1, 2026). The first is about ingredients. Salt forms such as semaglutide sodium and semaglutide acetate are, in FDA's view, different active ingredients, and FDA says it is "not aware of any lawful basis" for their use in compounding.

The second is about how products are presented. FDA lists among its red flags for consumers:

  • claims that a compounded drug is the same as an FDA-approved drug;
  • prices that seem too good to be true;
  • labels with false information, naming pharmacies that don't exist or that didn't make the product.

The same page reports adverse events. As of May 31, 2026, FDA had received 990 reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and it says these are likely under-reported. We pass the figures on as FDA states them; they are not a measure of any one product.

What FDA's warning letters to telehealth companies targeted

Marketing claims, not compounding as such. FDA has issued warning letters to telehealth sellers of compounded GLP-1s in several rounds, including letters dated September 2025, February 20, 2026 and June 8, 2026. FDA announced on March 3, 2026 that the February round comprised 30 letters, and the June round was reported at 25.

The letters cited claims such as "contains the same active ingredient as FDA-approved medications", and brand presentation that implied the telehealth company was the compounder. A warning letter sets out FDA's view of a violation; it isn't a court finding. FDA publishes the letters on fda.gov, among them ones dated February 20, 2026 to Lean Rx Inc, doing business as SkinnyRx, and June 8, 2026 to Altru Telehealth, if you want to read the agency's wording in full. FDA has separately warned telehealth companies marketing unapproved drugs such as retatrutide.

For a merchant, the letters are a list of phrases to keep out of ads, landing pages and checkout copy. The wider set of FDA and FTC actions on GLP-1 marketing is covered in GLP-1 advertising rules for telehealth.

What is FDA's 503B bulks proposal?

A proposal, as of November 2026, not to place semaglutide, tirzepatide and liraglutide on FDA's list of bulk drug substances for outsourcing-facility compounding. It appeared in a Federal Register notice reported on May 1, 2026, and as far as we know FDA hasn't finalized it.

The proposal only concerns §503B, so it bears on outsourcing facilities, not on 503A pharmacies. If your program sources from a 503B facility, the final notice is the date to watch, and your underwriter will want to know what you would do with prepaid memberships if your supply changed.

What a processor will ask you because of all this

Precise product and pharmacy details, and a plan for what happens if FDA's position moves. The questions we'd expect in a file review:

  1. Which products do you sell, by active ingredient exactly as labelled, including whether any is a salt form?
  2. Which pharmacy makes each one, and does it operate under §503A or as a registered §503B outsourcing facility?
  3. On what basis does the pharmacy say it can compound the product now that the shortage has ended, and has your regulatory counsel reviewed that?
  4. Do your ads, product pages or checkout say or imply that the product is the same as an FDA-approved drug, or that you are the compounder?
  5. Have you or your pharmacy received FDA correspondence about these products?
  6. If a product became unavailable, how would you handle prepaid plans, renewals and refunds?

This is a summary of FDA's public statements, not legal advice. The rest of what underwriters ask a weight-loss program is in payment processing for GLP-1 telehealth. VyaPay runs its own processor and underwrites in-house, so these questions come from the team that makes the risk decision. If you want to go through them before you apply, talk to VyaPay.

Frequently asked questions

Is compounded tirzepatide legal?

FDA's position, as of November 2026, is that with the tirzepatide shortage resolved and both transition periods over since March 2025, compounders can't rely on the shortage to make essentially copies. That isn't a ban on compounding and it isn't a ruling on any one product; whether a particular product is lawful is for regulatory counsel.

Is compounded semaglutide the same as the FDA-approved drug?

FDA treats that claim as a red flag, and its warning letters cited "same active ingredient" wording. Its consumer guidance discusses compounded versions under the heading of unapproved GLP-1 drugs.

What is semaglutide sodium?

A salt form of semaglutide. FDA considers salt forms, sodium and acetate among them, to be different active ingredients from the one in the approved drug, and says it is aware of no lawful basis for compounding with them.

Could FDA's position change again?

Parts of it are still moving. The 503B bulks proposal wasn't final as of November 2026 as far as we know, and FDA updates its consumer page. Check fda.gov for current status before relying on any date here.

Sources

Talk to the team that underwrites you

Tell us what you prescribe or sell, how you bill and who your pharmacy partners are. You'll be talking to the people who run VyaPay's processor and make its risk decisions.

or call 833-4-VYAPAY

Let’s meet up!

Tell us about your business and someone from our team will reach out.